UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2004
----------------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
-------------- --------------
Commission file number 1-11353
------------------------------
LABORATORY CORPORATION OF AMERICA HOLDINGS
- ------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 13-3757370
- ------------------------------- -------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
- ---------------------------------------------------- ----------
(Address of principal executive offices) (Zip code)
(336) 229-1127
----------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports) and (2) has been subject to such filing requirements
for the past 90 days. Yes X No
----- -----
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Rule 12b-2 of the Exchange Act. Yes X No
----- -----
The number of shares outstanding of the issuer's common stock is
139,646,910 shares, net of treasury stock as of July 30, 2004.
INDEX
PART I. Financial Information
Item 1 Financial Statements:
Condensed Consolidated Balance Sheets (unaudited)
June 30, 2004 and December 31, 2003
Condensed Consolidated Statements of Operations (unaudited)
Six and three months ended June 30, 2004 and 2003
Condensed Consolidated Statements of Changes in
Shareholders' Equity (unaudited)
Six months ended June 30, 2004 and 2003
Condensed Consolidated Statements of Cash Flows
(unaudited) Six months ended June 30, 2004 and 2003
Notes to Unaudited Condensed Consolidated Financial Statements
Item 2 Management's Discussion and Analysis of Financial
Condition and Results of Operations
Item 3 Quantitative and Qualitative Disclosures about
Market Risk
Item 4 Controls and Procedures
PART II. OTHER INFORMATION
Item 1 Legal Proceedings
Item 2 Changes in Securities, Use of Proceeds and Issuer
Purchases of Equity Securities
Item 4 Submission of Matters to a Vote of Security Holders
Item 6 Exhibits and Reports on Form 8-K
PART I - FINANCIAL INFORMATION
Item 1. Financial Information
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(Unaudited)
June 30, December 31,
2004 2003
---------- ------------
ASSETS
Current assets:
Cash and cash equivalents $ 182.2 $ 123.0
Accounts receivable, net 452.5 432.5
Supplies inventories 47.8 47.0
Prepaid expenses and other 25.3 36.3
Deferred income taxes 13.0 19.1
-------- --------
Total current assets 720.8 657.9
Property, plant and equipment, net 356.0 361.3
Goodwill 1,305.9 1,285.9
Intangible assets, net 567.0 571.4
Investments in equity affiliates 493.6 505.3
Other assets, net 31.6 33.1
-------- --------
$ 3,474.9 $ 3,414.9
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 78.5 $ 73.0
Accrued expenses and other 185.6 161.1
Zero coupon-subordinated notes 528.4 523.2
Current portion of long-term debt 0.2 0.3
-------- --------
Total current liabilities 792.7 757.6
5 1/2% senior notes 353.6 353.8
Long-term debt, less current portion 2.2 2.5
Capital lease obligations 3.7 4.4
Deferred income taxes 283.7 273.4
Other liabilities 117.1 127.3
Commitments and contingencies
Shareholders' equity:
Preferred stock, $0.10 par value; 30,000,000
shares authorized; shares issued: none -- --
Common stock, $0.10 par value; 265,000,000
shares authorized;149,822,486 and
148,855,110 shares issued and outstanding
at June 30, 2004 and December 31,
2003, respectively 15.0 14.9
Additional paid-in capital 1,470.1 1,440.9
Retained earnings 772.7 587.1
Treasury stock, at cost; 10,289,653 shares
and 5,521,620 shares at June 30, 2004 and
December 31, 2003, respectively (348.1) (159.3)
Unearned restricted stock compensation (13.5) (22.4)
Accumulated other comprehensive loss 25.7 34.7
-------- --------
Total shareholders' equity 1,921.9 1,895.9
-------- --------
$ 3,474.9 $ 3,414.9
======== ========
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
--------------------- ---------------------
2004 2003 2004 2003
--------------------- ---------------------
Net sales $ 784.3 $ 743.7 $ 1,536.8 $ 1,455.9
Cost of sales 444.6 427.2 879.5 842.9
-------- -------- -------- --------
Gross profit 339.7 316.5 657.3 613.0
Selling, general and
administrative expenses 165.0 164.1 328.0 327.4
Amortization of intangibles
and other assets 10.5 9.5 20.8 18.0
-------- -------- -------- --------
Operating income 164.2 142.9 308.5 267.6
Other income (expenses):
Interest expense (9.3) (10.0) (18.6) (21.4)
Income from equity
investments, net 12.1 11.3 24.7 21.1
Investment income 0.4 2.4 0.9 4.7
Other, net (0.8) (0.2) (0.9) (0.3)
-------- -------- -------- --------
Earnings before income taxes 166.6 146.4 314.6 271.7
Provision for income taxes 68.3 60.0 129.0 111.4
-------- -------- -------- --------
Net earnings $ 98.3 $ 86.4 $ 185.6 $ 160.3
======== ======== ======== ========
Basic earnings per
common share $ 0.70 $ 0.60 $ 1.32 $ 1.10
Diluted earnings per
common share $ 0.70 $ 0.60 $ 1.30 $ 1.10
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(DOLLARS AND SHARES IN MILLIONS)
(Unaudited)
Additional
Common Stock Paid-in Retained
Shares Amount Capital Earnings
-------------- -------- --------
PERIOD ENDED JUNE 30, 2003
Balance at beginning of year 147.8 $ 14.8 $1,406.5 $ 266.1
Comprehensive earnings:
Net earnings -- -- -- 160.3
Other comprehensive loss:
Foreign currency translation
adjustments -- -- -- --
Comprehensive earnings
Issuance of common stock 0.3 -- 5.9 --
Issuance of restricted stock
awards -- -- 0.2 --
Amortization of unearned
restricted stock compensation -- -- -- --
Income tax benefit from stock
options exercised -- -- 2.7 --
Assumption of vested stock
options in connection with
acquisition -- -- 8.5 --
Surrender of restricted stock
awards -- -- (1.0) --
Purchase of common stock -- -- -- --
----- ----- ------- ------
BALANCE AT JUNE 30, 2003 148.1 $ 14.8 $1,422.8 $ 426.4
===== ===== ======= ======
PERIOD ENDED JUNE 30, 2004
Balance at beginning of year 148.9 $ 14.9 $1,440.9 $ 587.1
Comprehensive earnings:
Net earnings -- -- -- 185.6
Other comprehensive loss:
Foreign currency translation
adjustments -- -- -- --
Tax effect of other
comprehensive loss
adjustments -- -- -- --
Comprehensive earnings
Issuance of common stock 0.9 0.1 22.9 --
Issuance of restricted stock
awards -- -- 0.7 --
Amortization of unearned
restricted stock compensation -- -- -- --
Income tax benefit from stock
options exercised -- -- 5.7 --
Surrender of restricted stock
awards -- -- (0.1) --
Purchase of common stock -- -- -- --
----- ----- ------- -------
BALANCE AT JUNE 30, 2004 149.8 $ 15.0 $1,470.1 $ 772.7
===== ===== ======= =======
(continued)
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CONTINUED)
(DOLLARS AND SHARES IN MILLIONS)
(Unaudited)
Unearned Accumulated
Restricted Other Total
Treasury Stock Comprehensive Shareholders'
Stock Compensation Loss Equity
-------- ------------ ------------- -------------
PERIOD ENDED JUNE 30, 2003
Balance at beginning of year $ (4.4) $ (41.4) $ (29.9) $1,611.7
Comprehensive earnings:
Net earnings -- -- -- 160.3
Other comprehensive loss:
Foreign currency
translation adjustments -- -- 71.3 71.3
Tax effect of other
comprehensive loss
adjustments -- -- (28.6) (28.6)
Comprehensive earnings 203.0
Issuance of common stock -- -- -- 5.9
Issuance of restricted stock
awards -- (0.2) -- --
Amortization of unearned
restricted stock compensation -- 8.6 -- 8.6
Income tax benefit from stock
options exercised -- -- -- 2.7
Assumption of vested stock
options in connection with
acquisition -- -- -- 8.5
Surrender of restricted stock
awards (4.8) 1.0 -- (4.8)
Purchase of common stock (86.4) -- -- (86.4)
------ ------ ------- -------
BALANCE AT JUNE 30, 2003 $ (95.6) $ (32.0) $ 12.8 $1,749.2
====== ====== ======= =======
PERIOD ENDED JUNE 30, 2004
Balance at beginning of year $(159.3) $ (22.4) $ 34.7 $1,895.9
Comprehensive earnings:
Net earnings -- -- -- 185.6
Other comprehensive loss:
Foreign currency
translation adjustments -- -- (15.1) (15.1)
Tax effect of other
comprehensive loss
adjustments -- -- 6.1 6.1
Comprehensive earnings 176.6
Issuance of common stock -- -- -- 23.0
Issuance of restricted stock
awards -- (0.7) -- --
Amortization of unearned
restricted stock compensation -- 9.5 -- 9.5
Income tax benefit from stock
options exercised -- -- -- 5.7
Surrender of restricted stock
awards (6.7) 0.1 -- (6.7)
Purchase of common stock (182.1) -- -- (182.1)
------ ------- ------- -------
BALANCE AT JUNE 30, 2004 $(348.1) $ (13.5) $ 25.7 $1,921.9
====== ======= ======= =======
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(Unaudited)
Six Months Ended
June 30,
-------------------------
2004 2003
-------------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings $ 185.6 $ 160.3
Adjustments to reconcile net earnings to
net cash provided by operating activities:
Depreciation and amortization 69.6 66.7
Stock compensation 9.5 8.6
(Gain) loss on sale of assets 0.5 (0.1)
Accreted interest on zero coupon-
subordinated notes 5.2 5.1
Deferred income taxes 23.8 15.0
Change in assets and liabilities (net of
effects of acquisitions):
Increase in accounts receivable, net (19.9) (18.0)
Increase in inventories (0.1) (2.4)
Decrease in prepaid expenses and other 11.0 3.6
Increase(decrease) in accounts payable 5.5 (5.7)
Increase in accrued expenses and other
expenses and other 3.6 25.1
------- -------
Net cash provided by operating activities 294.3 258.2
------- -------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (42.6) (37.4)
Proceeds from sale of assets 1.3 0.6
Deferred payments on acquisitions (3.8) (6.3)
Proceeds from sale of marketable securities -- 50.4
Distributions from equity affiliates in
excess of cumulative earnings -- 1.6
Acquisition of licensing technology (0.5) --
Acquisition of businesses, net of
cash acquired (34.6) (636.0)
------- -------
Net cash used for investing activities (80.2) (627.1)
------- -------
(continued)
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(Unaudited)
Six Months Ended
June 30,
--------------------------
2004 2003
--------------------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from bridge loan $ -- $ 350.0
Payments on bridge loan -- (350.0)
Proceeds from revolving credit
facilities -- 265.0
Payments on revolving credit
facilities -- (180.0)
Proceeds from senior note offering -- 350.0
Payments on other long-term debt (0.4) (0.4)
Termination of interest rate swap
agreements -- 5.3
Debt issuance costs -- (7.3)
Payments on long-term lease obligations (0.7) (0.7)
Purchase of common stock (176.2) (91.2)
Net proceeds from issuance of stock to
employees 23.0 5.8
------- -------
Net cash (used)provided by financing
activities (154.3) 346.5
------- -------
Effect of exchange rate changes on cash
and cash equivalents (0.6) (0.1)
------- -------
Net (decrease) increase in cash and
cash equivalents 59.2 (22.5)
Cash and cash equivalents at
beginning of period 123.0 56.4
------- -------
Cash and cash equivalents at
end of period $ 182.2 $ 33.9
======= =======
Supplemental schedule of cash
flow information:
Cash paid during the period for:
Interest $ 9.6 $ 2.9
Income taxes, net of refunds 56.5 70.8
Disclosure of non-cash financing
and investing activities:
Issuance of restricted stock awards 0.7 0.2
Surrender of restricted stock awards 6.7 4.8
Assumption of vested stock options -- 8.5
Accrued repurchases of common stock 5.9 --
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
1. BASIS OF FINANCIAL STATEMENT PRESENTATION
The condensed consolidated financial statements include the
accounts of Laboratory Corporation of America Holdings and its
wholly owned subsidiaries (the "Company") after elimination of all
material intercompany accounts and transactions. On January 17,
2003, the Company completed the acquisition of DIANON Systems, Inc.,
(DIANON) a leading U.S. provider of anatomic pathology and oncology
testing services. Disclosure of certain business combination
transactions is included in Note 7 - Business Acquisition. The
Company operates in one business segment.
The financial statements of the Company's foreign subsidiaries
are measured using the local currency as the functional currency.
Assets and liabilities are translated at exchange rates as of the
balance sheet date. Revenues and expenses are translated at average
monthly exchange rates prevailing during the period. Resulting
translation adjustments are included in "Accumulated other
comprehensive earnings(loss)".
The accompanying condensed consolidated financial statements of
the Company are unaudited. In the opinion of management, all
adjustments (which include only normal recurring accruals) necessary
for a fair presentation of such financial statements have been
included. Interim results are not necessarily indicative of results
for a full year.
The financial statements and notes are presented in accordance
with the rules and regulations of the Securities and Exchange
Commission and do not contain certain information included in the
Company's 2003 annual report on Form 10-K. Therefore, the interim
statements should be read in conjunction with the consolidated
financial statements and notes thereto contained in the Company's
annual report.
2. EARNINGS PER SHARE
Basic earnings per share is computed by dividing net earnings
by the weighted average number of common shares outstanding.
Dilutive earnings per share is computed by dividing net earnings by
the weighted average number of common shares outstanding plus
potentially dilutive shares, as if they had been issued at the
beginning of the period presented. Potentially dilutive common
shares result primarily from the Company's restricted stock awards
and outstanding stock options.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
The following represents a reconciliation of the weighted
average shares used in the calculation of basic and diluted earnings
per share:
Three Months Six Months
Ended June 30, Ended June 30,
------------------------ ----------------------
2004 2003 2004 2003
------------------------ ------------------------
Basic 140,053,538 144,562,713 140,923,330 145,222,214
Assumed conversion/
exercise of:
Stock options 775,912 485,967 803,187 381,169
Restricted stock awards 444,263 -- 609,980 103,769
----------- ----------- ----------- -----------
Diluted 141,273,713 145,048,680 142,336,497 145,707,152
=========== =========== =========== ===========
The following table summarizes the potential common shares not
included in the computation of diluted earnings per share
because their impact would have been antidilutive:
June 30,
2004 2003
----------------------
Stock Options 1,492,611 4,432,902
The Company's zero coupon-subordinated notes are
contingently convertible into 9,977,634 shares of common stock
and are not currently included in the diluted earnings per share
calculation because these notes were not convertible according
to their terms at June 30, 2004. Holders of the zero coupon-
subordinated notes may require the Company to purchase all or a
portion of their notes on September 11, 2004, 2006 and 2011 at
prices ranging from $712.97 to $819.54 per note. The Company may
choose to pay the purchase price in cash or common stock or a
combination of cash and common stock. If the holders elect to
require the Company to purchase their notes, it is the Company's
current intention to retire the notes by a cash payment. However,
future market conditions are subject to change. Should the
holders put the notes to the Company on any of the dates above,
the Company believes that it will be able to satisfy this
contingent obligation with cash on hand, borrowings on the
revolving credit facility, and additional financing if necessary.
3. STOCK COMPENSATION PLANS
During February 2004, the Company granted 1,738,800 options at
a price of $39.00 under its 2000 Stock Incentive Plan.
During March 2004, the Company recorded aggregate awards of
11,329 shares of restricted stock at a weighted average price of
$35.29 to one of the principals in the Company's research and
development joint venture and a non-employee director under its 2000
Stock Incentive Plan.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
During May 2004, the Company made awards of 7,728 shares of
restricted stock and 11,904 options to its non-employee directors at
a price of $38.80 under its 2000 Stock Incentive Plan.
The tax benefits associated with the exercise of non-qualified
stock options reduced taxes currently payable by $5.7 and $2.7 for
the six months ended June 30, 2004 and 2003, respectively. Such
benefits are credited to additional paid-in-capital.
The Company applies the provisions of APB Opinion No. 25 in
accounting for its employee stock option and stock purchase
plans and, accordingly, no compensation cost has been recognized
for these plans in the financial statements. Had the Company
determined compensation cost for these two plans based on the
fair value method as defined in SFAS No. 123, the impact on the
Company's net earnings on a pro forma basis is indicated below:
Three Months Ended Six Months Ended
June 30, June 30,
------------------ ----------------
2004 2003 2004 2003
------------------ ----------------
Net earnings, as reported $ 98.3 $ 86.4 $185.6 $160.3
Add: Restricted stock-based
compensation Under APB 25 3.0 4.1 9.5 8.6
Deduct: Total stock-based
compensation expense determined
under the fair value method for
all awards, net of related tax
effects (9.1) (10.7) (21.7) (21.7)
----- ----- ----- -----
Pro forma net income $ 92.2 $ 79.8 $173.4 $147.2
===== ===== ===== =====
Basic earnings per
common share As reported 0.70 0.60 1.32 1.10
Pro forma 0.66 0.55 1.23 1.01
Diluted earnings per
common share As reported 0.70 0.60 1.30 1.10
Pro forma 0.65 0.55 1.22 1.01
4. STOCK REPURCHASE PROGRAM
On December 17, 2003, the Company's Board of Directors
authorized a stock repurchase program under which the Company may
purchase up to an aggregate of $250.0 of its common stock from time-
to-time, beginning in the first quarter of 2004. During the first
six months of 2004, the Company purchased approximately 4.6 million
shares of its common stock totaling $182.1 with cash flow from
operations. It is the Company's intention to fund future purchases
of its common stock with cash flow from operations.
5. SENIOR CREDIT FACILITIES
On January 13, 2004, the Company entered into a new $150.0 364-
day revolving credit facility with Credit Suisse First Boston,
acting as Administrative Agent, and a group of financial
institutions to replace the existing $150.0 364-day revolving credit
facility, which had terminated. The $200.0 three-year revolving
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
credit facility was amended on January 14, 2003 and expires on
February 18, 2005. These credit facilities bear interest at varying
rates based upon the Company's credit rating with Standard & Poor's
Ratings Services. There were no balances outstanding on the
Company's senior credit facilities at June 30, 2004.
The senior credit facilities are available for general
corporate purposes, including working capital, capital
expenditures, funding of share repurchases and other payments,
and acquisitions. The agreements contain certain debt covenants
which require that the Company maintain leverage and interest
coverage ratios of 2.5 to 1.0 and 5.0 to 1.0, respectively. Both
ratios are calculated in relation to EBITDA (Earnings Before
Interest, Taxes, Depreciation, and Amortization). The covenants
also limit the payment of dividends. The Company is in
compliance with all covenants at June 30, 2004.
6. DERIVATIVE FINANCIAL INSTRUMENTS
Interest rate swap agreements, which have been used by the
Company from time to time in the management of interest rate
exposure, are accounted for at fair value. Amounts to be paid or
received under such agreements are recognized as interest income or
expense in the periods in which they accrue.
The Company's zero coupon-subordinated notes contain the
following three features that are considered to be embedded
derivative instruments under Statement of Financial Accounting
Standards ("SFAS") No. 133 "Accounting for Derivative
Instruments and Hedging Activities":
1) The Company will pay contingent cash interest on the zero
coupon subordinated notes after September 11, 2006, if the
average market price of the notes equals 120% or more of
the sum of the issue price, accrued original issue discount
and contingent additional principal, if any, for a
specified measurement period.
2) Contingent additional principal will accrue on the zero
coupon-subordinated notes during the two-year period from
September 11, 2004 to September 11, 2006, if the Company's
stock price is at or below specified thresholds.
3) Holders may surrender zero coupon-subordinated notes for
conversion during any period in which the rating assigned
to the zero coupon-subordinated notes by Standard & Poor's
Ratings Services is BB- or lower.
Based upon independent appraisals, these embedded derivatives
had no fair market value at June 30, 2004 and 2003.
7. BUSINESS ACQUISITION - DIANON SYSTEMS, INC.
On January 17, 2003, the Company completed the acquisition of
all of the outstanding shares of DIANON Systems, Inc. (DIANON) for
$47.50 per share in cash, or approximately $595.6 including
transaction fees and expenses, and converted approximately 390,000
vested DIANON employee stock options into approximately 690,000
vested Company options valued at $8.5. The transaction total of
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
approximately $604.5 was funded by a combination of cash on hand,
borrowings under the Company's senior credit facilities and a bridge
loan facility.
The following unaudited pro forma combined financial
information for the six months ended June 30, 2003 assumes that the
DIANON acquisition, which was closed by the Company on January 17,
2003, was acquired on January 1, 2003:
Six Months Ended
June 30, 2003
----------------
Net sales $1,463.9
Net earnings 160.4
Diluted earnings
per common share $ 1.10
8. GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill (net of
accumulated amortization) for the six-month period ended June 30,
2004 and for the year ended December 31, 2003 are as follows:
June 30, 2004 December 31, 2003
------------- -----------------
Balance as of January 1 $ 1,285.9 $ 910.1
Goodwill acquired during
the period 18.8 388.7
Adjustments to goodwill 1.2 (12.9)
-------- --------
Balance at end of period $ 1,305.9 $ 1,285.9
======== ========
The components of identifiable intangible assets are as follows:
June 30, 2004 December 31, 2003
----------------------- -----------------------
Gross Gross
Carrying Accumulated Carrying Accumulated
Amount Amortization Amount Amortization
----------------------- -----------------------
Customer lists $ 596.1 $ 132.8 $ 582.5 $ 118.1
Patents, licenses
and technology 67.7 14.5 67.2 11.1
Non-compete
agreements 25.4 19.2 23.0 18.1
Trade name 49.5 5.2 49.6 3.6
------- ------- ------- -------
$ 738.7 $ 171.7 $ 722.3 $ 150.9
======= ======= ======= =======
Amortization of intangible assets for the six month and three
month periods ended June 30, 2004 was $20.8 and $10.5, respectively,
and $18.0 and $9.5 for the six month and three month periods ended
June 30, 2003. Amortization expense for the net carrying amount of
intangible assets is estimated to be $21.0 for the remainder of
fiscal 2004, $42.3 in fiscal 2005, $40.9 in fiscal 2006, $39.4 in
fiscal 2007, and $37.2 in fiscal 2008.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
9. RESTRUCTURING RESERVES
The following represents the Company's restructuring activities
for the period indicated:
Lease and
Severance Other Facility
Costs Costs Total
--------- -------------- --------
Balance at December 31, 2003 $ 4.0 $26.8 $30.8
Cash payments (1.3) (2.9) (4.2)
Reclassifications non-cash items -- (1.7) (1.7)
Acquisition integration 1.2 2.7 3.9
---- ---- ----
Balance at June 30, 2004 $ 3.9 $24.9 $28.8
==== ==== ====
Current $14.3
Non-current 14.5
----
$28.8
====
10. COMMITMENTS AND CONTINGENCIES
The Company is involved in litigation purporting to be a nation-wide
class action involving the alleged overbilling of patients who are
covered by private insurance. The Company has reached a settlement
with the class that will not materially differ from accruals
previously established or have a material adverse effect on the
Company. The Company has now substantially implemented its
obligations under the settlement. On January 9, 2001, the Company
was served with a complaint in North Carolina which purported to be a
class action and made claims similar to those referred to above.
That claim has now been dismissed with prejudice.
On June 24, 2003, the Company and certain of its executive
officers were sued in the United States District Court for the Middle
District of North Carolina in the first of a series of putative
shareholder class actions alleging securities fraud. Since that
date, at least five other complaints containing substantially
identical allegations have been filed against the Company and certain
of the Company's executive officers. Each of the complaints alleges
that the defendants violated the federal securities laws by making
material misstatements and/or omissions that caused the price of the
Company's stock to be artificially inflated between February 13 and
October 3, 2002. The plaintiffs seek certification of a class of
substantially all persons who purchased shares of the Company's stock
during that time period and unspecified monetary damages. These six
cases have been consolidated and will proceed as a single case. The
defendants deny any liability and intend to defend the case
vigorously. The plaintiffs have recently filed a consolidated amended
complaint. On July 16, 2004, the defendants filed a motion to
dismiss this complaint and continue to defend the case vigorously. At
this time, it is premature to make any assessment of the potential
outcome of the cases or whether they could have a material adverse
effect on the Company's financial condition.
The Company is the appellant in a patent case originally filed
in the United States District Court for the District of Colorado.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
The Company has disputed liability and contested the case vigorously.
After a jury trial, the district court entered judgment against the
Company for patent infringement, with total damages and attorneys
fees payable by the Company of approximately $7.8 million. The
Company appealed the case to the United States Court of Appeals for
the Federal Circuit. On June 8, 2004, that Court affirmed the
judgment against the Company. On June 22, 2004 the Company filed a
request for rehearing of the decision. The Company plans to continue
to vigorously contest the Judgment until it exhausts all reasonable
appellate rights. The Company has recorded a reserve for this
potential settlement.
The Company is a party to two lawsuits involving Chiron Inc.
relating to Hepatitis C and HIV testing. Chiron asserts that the
Company has infringed on Chiron's patents in each of these areas.
The Company denies liability and intends to contest the suits
vigorously. It is premature at this juncture to assess the likely
outcome of these matters, or to determine whether they will have a
material effect on the Company.
The Company is also involved in various claims and legal actions
arising in the ordinary course of business. These matters include,
but are not limited to, intellectual property disputes, professional
liability, employee related matters, and inquiries from governmental
agencies and Medicare or Medicaid payors and managed care payors
requesting comment on allegations of billing irregularities that are
brought to their attention through billing audits or third parties.
In the opinion of management, based upon the advice of counsel and
consideration of all facts available at this time, the ultimate
disposition of these matters is not expected to have a material
adverse effect on the financial position, results of operations or
liquidity of the Company. The Company is also named from time to
time in suits brought under the qui tam provisions of the False
Claims Act. These suits typically allege that the Company has made
false statements and/or certifications in connection with claims for
payment from federal health care programs. They may remain under
seal (hence, unknown to the Company) for some time while the
government decides whether to intervene on behalf of the qui tam
plaintiff. Such claims are an inevitable part of doing business in
the health care field today and, in the opinion of management, based
upon the advice of counsel and consideration of all facts available
at this time, the ultimate disposition of those qui tam matters
presently known to the Company is not expected to have a material
adverse effect on the financial position, results of operations or
liquidity of the Company.
The Company believes that it is in compliance in all material
respects with all statutes, regulations and other requirements
applicable to its clinical laboratory operations. The clinical
laboratory testing industry is, however, subject to extensive
regulation, and many of these statutes and regulations have not been
interpreted by the courts. There can be no assurance therefore that
applicable statutes and regulations might not be interpreted or
applied by a prosecutorial, regulatory or judicial authority in a
manner that would adversely affect the Company. Potential sanctions
for violation of these statutes and regulations include significant
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
fines and the loss of various licenses, certificates and
authorizations.
Under the Company's present insurance programs, coverage is
obtained for catastrophic exposures as well as those risks required
to be insured by law or contract. The Company is responsible for the
uninsured portion of losses related primarily to general,
professional and vehicle liability, certain medical costs and
workers' compensation. The self-insured retentions are on a per
occurrence basis without any aggregate annual limit. Provisions for
losses expected under these programs are recorded based upon the
Company's estimates of the aggregated liability of claims incurred.
At June 30, 2004 and 2003, the Company had provided letters of credit
aggregating approximately $52.9 and $46.1 respectively, primarily in
connection with certain insurance programs.
11. PENSION AND POSTRETIREMENT PLANS
Substantially all employees of the Company are covered by a
defined benefit retirement plan (the "Company Plan"). The benefits
to be paid under the Company Plan are based on years of credited
service and average final compensation. The Company's policy is to
fund the Company Plan with at least the minimum amount required by
applicable regulations.
The Company has a second defined benefit plan which covers its
senior management group that provides for the payment of the
difference, if any, between the amount of any maximum limitation on
annual benefit payments under the Employee Retirement Income
Security Act of 1974 and the annual benefit that would be payable
under the Company Plan but for such limitation. This plan is an
unfunded plan.
The components of net periodic pension cost for both of the
defined benefit plans are summarized as follows:
Three Months Six Months
Ended June 30, Ended June 30,
----------------- -----------------
2004 2003 2004 2003
----------------- -----------------
Components of net periodic
benefit cost
Service Cost $ 3.6 $ 3.1 $ 6.8 $ 6.2
Interest Cost 3.2 3.2 6.3 6.4
Expected return on plan assets (4.2) (3.2) (7.9) (6.4)
Net amortization and deferral 0.4 0.9 0.8 1.8
----- ----- ----- -----
Net periodic pension cost $ 3.0 $ 4.0 $ 6.0 $ 8.0
===== ===== ===== =====
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
The Company assumed obligations under a subsidiary's
postretirement medical plan. Coverage under this plan is restricted
to a limited number of existing employees of the subsidiary. This
plan is unfunded and the Company's policy is to fund benefits as
claims are incurred. The components of postretirement benefit
expense are as follows:
Three Months Six Months
Ended June 30, Ended June 30,
--------------- ----------------
2004 2003 2004 2003
--------------- ----------------
Components of post retirement
benefit expense
Service Cost $ 0.3 $ 0.2 $ 0.5 $ 0.4
Interest Cost 0.8 0.8 1.8 1.6
Net amortization and deferral (0.5) (0.5) (1.0) (1.0)
Amortization of actuarial loss 0.3 0.2 0.7 0.4
----- ----- ----- ------
Postretirement benefit expense $ 0.9 $ 0.7 $ 2.0 $ 1.4
===== ===== ===== ======
The Company previously disclosed in its financial
statements for the year ended December 31, 2003, that it
expected to contribute $34.6 to its defined pension plan in
2004. As of June 30, 2004, $20.6 of contributions have been
made. The Company presently anticipates contributing an
additional $14.0 to fund its pension plan in 2004 for a total of
$34.6.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING STATEMENTS
The Company has made in this report, and from time to time
may otherwise make in its public filings, press releases and
discussions by Company management, forward-looking statements
concerning the Company's operations, performance and financial
condition, as well as its strategic objectives. Some of these
forward-looking statements can be identified by the use of
forward-looking words such as "believes", "expects", "may",
"will", "should", "seeks", "approximately", "intends", "plans",
"estimates", or "anticipates" or the negative of those words or
other comparable terminology. Such forward-looking statements
are subject to various risks and uncertainties and the Company
claims the protection afforded by the safe harbor for forward-
looking statements contained in the Private Securities
Litigation Reform Act of 1995. Actual results could differ
materially from those currently anticipated due to a number of
factors in addition to those discussed elsewhere herein and in
the Company's other public filings, press releases and
discussions with Company management, including:
1. changes in federal, state, local and third party payor
regulations or policies (or in the interpretation of current
regulations) affecting governmental and third-party
reimbursement for clinical laboratory testing;
2. adverse results from investigations of clinical laboratories
by the government, which may include significant monetary
damages and/or exclusion from the Medicare and Medicaid
programs;
3. loss or suspension of a license or imposition of a fine or
penalties under, or future changes in, the law or regulations of
the Clinical Laboratory Improvement Act of 1967, and the Clinical
Laboratory Improvement Amendments of 1988, or those of Medicare,
Medicaid or other federal, state or local agencies;
4. failure to comply with the Federal Occupational Safety and
Health Administration requirements and the Needlestick Safety
and Prevention Act which may result in penalties and loss of
licensure;
5. failure to comply with HIPAA, which could result in
significant fines;
6. failure of third party payors to complete testing with the
Company, or accept or remit transactions in HIPAA-required
standard transaction and code set format, could result in an
interruption in the Company's cash flow;
7. increased competition, including price competition;
8. changes in payor mix, including an increase in capitated
managed-cost health care;
9. failure to obtain and retain new customers and alliance
partners, or a reduction in tests ordered or specimens
submitted by existing customers;
10.failure to integrate newly acquired businesses and the cost
related to such integration;
11.adverse results in litigation matters;
12.inability to attract and retain experienced and qualified
personnel;
13.failure to maintain the Company's days sales outstanding
levels;
14.decrease in credit ratings by Standard & Poor's and/or
Moody's;
15.failure to develop or acquire licenses for new or improved
technologies, or if customers use new technologies to perform
their own tests;
16.inability to commercialize newly licensed tests or
technologies or to obtain appropriate reimbursements for such
tests, which could result in impairment in the value of
certain capitalized licensing costs;
17.inability to obtain and maintain adequate patent and other
proprietary rights protection of the Company's products and
services and successfully enforce the Company's proprietary
rights;
18.the scope, validity and enforceability of patents and other
proprietary rights held by third parties which might have an
impact on the Company's ability to develop, perform, or
market the Company's tests or operate its business;
19.failure in the Company's information technology systems
resulting in an increase in testing turnaround time or
billing processes;
20.liabilities that result from the inability to comply with new
Corporate governance requirements; and
21.compliance by the Company with the Sarbanes-Oxley Act of
2002, including Section 404 of that Act which requires
management to report on, and our independent registered
public accounting firm to attest to and report on, our
internal controls, will require management to devote
substantial time and attention, which could prove to be
disruptive to product development and licensing, marketing
and other business activities and will require additional
legal, accounting and other expenses to implement the
requirements of these new rules.
RESULTS OF OPERATIONS
As discussed in the Company's Annual Report for the year
ended December 31, 2003, the Company acquired DIANON Systems, Inc.
on January 17, 2003. All dollar amounts are in millions.
Three Months ended June 30, 2004 compared with Three Months ended
June 30, 2003.
Net sales for the three months ended June 30, 2004 were
$784.3 an increase of $40.6, or approximately 5.5%, from $743.7
for the comparable 2003 period. The sales increase is a result of
an increase of approximately 5.0% in volume (primarily volume
growth in genomic and esoteric testing of approximately 10% as
well as volume growth of approximately 4% in the base business).
Price increased by approximately 0.5% for the quarter.
Cost of sales, which includes primarily laboratory and
distribution costs, was $444.6 for the three months ended June 30,
2004 compared to $427.2 in the corresponding 2003 period, an
increase of $17.4, or 4.1%. The increase in cost of sales is
primarily the result of increases in volume discussed above. Cost
of sales as a percentage of net sales was 56.7% for the three
months ended June 30, 2004 and 57.4% in the corresponding 2003
period. Cost of sales as a percentage of sales was impacted by
the Company's ongoing cost reduction programs.
Selling, general and administrative expenses increased to
$165.0 for the three months ended June 30, 2004 from $164.1 in the
same period in 2003. As a percentage of net sales, selling,
general and administrative expenses were 21.0% and 22.1% for the
three months ended June 30, 2004 and 2003, respectively. This
decrease in selling, general and administrative expenses as a
percentage of net sales is a result of realized synergies from the
Dynacare and DIANON acquisitions, as well as a reduced effective
bad debt expense rate, resulting from improved billing
performance.
The amortization of intangibles and other assets was $10.5
and $9.5 for the three months ended June 30, 2004 and 2003. The
increase in the amortization expense for the three months ended
June 30, 2004 is a result of small acquisitions.
Interest expense was $9.3 for the three months ended June 30,
2004 compared with $10.0 for the same period in 2003. This
decrease was a direct result of debt reductions following the
Company's financing of the DIANON acquisition in 2003.
Income from equity investments was $12.1 for the three months
ended June 30, 2004 compared with $11.3 for the same period in
2003. This income represents the Company's ownership share in
equity affiliates acquired as part of the Dynacare acquisition on
July 25, 2002. A significant portion of this income is derived from
investments in Ontario and Alberta, Canada, and is earned in
Canadian dollars.
The provision for income taxes as a percentage of earnings
before taxes was 41.0% for the three month periods June 30, 2004 and
2003.
Six Months ended June 30, 2004 compared with Six Months ended June
30, 2003.
Net sales for the six months ended June 30, 2004 were
$1,536.8, an increase of $80.9, or 5.6%, from $1,455.9 for the
same period in 2003. The sales increase is a result of an increase
in volume (primarily volume growth in genomic and esoteric testing
of approximately 10% as well as volume growth of approximately 5%
in the base business). Price was essentially flat for the first
six months.
Cost of sales, which includes primarily laboratory and
distribution costs, was $879.5 for the six months ended June 30,
2004 compared to $842.9 for the same period of 2003, an increase
of $36.6, or 4.3%. The increase in cost of sales is primarily the
result of increases in volume discussed above. Cost of sales as a
percentage of net sales was 57.2% for the six months ended June
30, 2004 and 57.9% for the same period in 2003. Cost of sales as a
percentage of sales was impacted by the Company's ongoing cost
reduction programs.
Selling, general and administrative expenses increased to
$328.0 for the six months ended June 30, 2004 from $327.4 for the
same period in 2003. As a percentage of net sales, selling,
general and administrative expenses were 21.3% and 22.5% for the
three months ended June 30, 2004 and 2003, respectively. This
decrease in selling, general and administrative expenses as a
percentage of net sales is a result of realized synergies from the
Dynacare and DIANON acquisitions, as well as a reduced effective
bad debt expense rate, resulting from improved billing
performance.
The amortization of intangibles and other assets was $20.8
and $18.0 for the six months ended June 30, 2004 and 2003. The
increase in the amortization expense for the six months ended June
30, 2004 is a result of small acquisitions.
Interest expense was $18.6 for the six months ended June 30,
2004 compared with $21.4 for the same period in 2003. This
decrease was a direct result of debt reductions following the
Company's financing of the DIANON acquisition in 2003.
The provision for income taxes as a percentage of earnings
before taxes was 41.0% for the six months ended June 30, 2004
compared to 40.8% for the six months ended June 30, 2003.
LIQUIDITY AND CAPITAL RESOURCES
Net cash provided by operating activities was $294.3 and $258.2
for the six months ended June 30, 2004 and June 30, 2003,
respectively. The increase in cash flows from operations primarily
resulted from improved earnings, the expansion of the business
through acquisitions, and the improvement of the Company's accounts
receivable days' sales oustanding ("DSO") to 52 days at June 30,
2004 from 54 days at June 30, 2003.
Capital expenditures were $42.6 and $37.4 at June 30, 2004 and
2003, respectively. The Company expects total capital expenditures
of approximately $90.0 to $100.0 in 2004. These expenditures are
intended to continue to improve information systems and further
automate laboratory processes. Such expenditures are expected to be
funded by cash flow from operations.
On December 17, 2003, the Company's Board of Directors
authorized a stock repurchase program under which the Company may
purchase up to an aggregate of $250.0 of its common stock from time-
to-time, beginning in the first quarter of 2004. During the first
six months of 2004, the Company purchased approximately 4.6 million
shares of its common stock totaling $182.1 with cash flow from
operations. It is the Company's intention to fund future purchases
of its common stock with cash flow from operations.
Based on current and projected levels of operations, coupled
with availability under its revolving credit facilities, the Company
believes it has sufficient liquidity to meet both its short-term and
long-term cash needs.
CONTRACTUAL CASH OBLIGATIONS
Payments Due by Period at June 30, 2004
---------------------------------------
< 1 Yr 1-3 Yrs 3-5 Yrs > 5 Yrs
---------------------------------------
Capital lease
obligations $ 1.4 $ 2.5 $ 1.2 $ --
Operating leases 57.5 75.3 34.1 25.3
Restructuring
obligations 2.3 6.4 5.9 6.4
Contingent future
licensing payments(a) 9.7 31.1 19.0 0.4
Royalty payments 0.3 1.8 2.0 --
5 1/2% Senior Notes -- -- -- 350.0
Zero Coupon-
Subordinated Notes 530.5(b) -- -- --
----- ----- ----- -----
Total contractual
Cash obligations $601.7 $117.1 $ 62.2 $382.1
===== ===== ===== =====
(a) Contingent future licensing payments will be made in the
event that certain events take place, such as the launch of
a specific test, the transfer of certain technology, and
when specified revenue milestones are met.
(b) Holders of the zero coupon-subordinated notes may require the
Company to purchase all or a portion of their notes on
September 11, 2004, 2006 and 2011 at prices ranging from
$712.97 to $819.54 per note. The Company may choose to pay
the purchase price in cash or common stock or a combination
of cash and common stock. If the holders elect to require
the Company to purchase their notes, it is the Company's
current intention to retire the notes by a cash payment.
However, future market conditions are subject to change.
Should the holders put the notes to the Company on any of
the dates above, the Company believes that it will be able
to satisfy this contingent obligation with cash on hand,
borrowings on the revolving credit facility, and additional
financing if necessary.
EITF NO 04-8 "THE EFFECT OF CONTINGENTLY CONVERTIBLE DEBT ON DILUTED
EARNINGS PER SHARE"
In July 2004, the Emerging Issues Task Force ("EITF") of
the Financial Accounting Standards Board provided a tentative
conclusion on EITF Issue No. 04-8, "The Effect of Contingently
Convertible Debt on Diluted Earnings per Share." Under the
EITF's tentative conclusion, contingently convertible shares
attached to a debt instrument are to be included in the
calculation of diluted earnings per share regardless of whether
the contingency has been met. Historically the Company has
followed the guidance of paragraph 30 of SFAS No. 128, "Earnings
Per Share", and excluded these contingently convertible shares
from its calculations of diluted earnings per share. If a final
consensus is reached in support of the tentative EITF
conclusion, the Company would be required to adopt the
provisions of EITF No 04-8 for its zero coupon-subordinated
notes for periods ending after December 15, 2004, including the
retroactive restatement of all diluted earnings per share
calculations for all periods presented. The EITF Issue No 04-8
is currently subject to a comment period and the EITF will
review the comments at its September 2004 meeting. Based on a
review of the provisions of the Issue No 04-8, the Company has
determined that the adoption would result in the reduction of
its diluted earnings per share. Using the "if converted" method
as if the zero coupon-subordinated notes had been converted as
of January 1, 2004, diluted income per share of common stock
from continuing operations would have been reduced by
approximately $0.03, to $0.67; and by $0.06, to $1.24; for the
three and six months ended June 30, 2004, respectively. However,
the exact amount of dilution cannot be determined until final
guidance is provided by the EITF.
ITEM 3. Quantitative and Qualitative Disclosure about
Market Risk
The Company addresses its exposure to market risks, principally
the market risk associated with changes in interest rates, through a
controlled program of risk management that has included in the past,
the use of derivative financial instruments such as interest rate
swap agreements. The Company had an interest rate swap agreement
with a major financial institution, solely to manage its interest
rate exposure on $175.0 million of its 5 1/2% senior notes. This
swap agreement was terminated during June 2003 and the Company
received net proceeds of $5.3 million. Although, as set forth
below, the Company's zero coupon-subordinated notes contain
features that are considered to be embedded derivative
instruments, the Company does not hold or issue derivative
financial instruments for trading purposes. The Company does not
believe that its exposure to market risk is material to the
Company's financial position or results of operations.
The Company's zero coupon-subordinated notes contain the
following three features that are considered to be embedded
derivative instruments under SFAS No. 133:
1) The Company will pay contingent cash interest on the zero
coupon-subordinated notes after September 11, 2006, if the
average market price of the notes equals 120% or more of the
sum of the issue price, accrued original issue discount and
contingent additional principal, if any, for a specified
measurement period.
2) Contingent additional principal will accrue on the zero
coupon-subordinated notes during the two-year period from
September 11, 2004 to September 11, 2006, if the Company's
stock price is at or below specified thresholds.
3) Holders may surrender zero coupon-subordinated notes for
conversion during any period in which the rating assigned to
the zero coupon-subordinated notes by Standard & Poor's
Ratings Services is BB- or lower.
Based upon independent appraisals, these embedded derivatives
had no fair value at June 30, 2004.
ITEM 4. Controls and Procedures
As of the end of the period covered by this Form 10-Q, the
Company carried out, under the supervision and with the
participation of the Company's management, including the
Company's Chief Executive Officer and Chief Financial Officer,
an evaluation of the effectiveness of the design and operation
of the Company's disclosure controls and procedures. Based on
the foregoing, the Company's Chief Executive Officer and Chief
Financial Officer concluded that the Company's disclosure
controls and procedures are effective in timely alerting them to
material information which is required to be included in the
periodic reports that the Company must file with the Securities
and Exchange Commission.
There were no significant changes in the Company's internal
controls or in other factors that could adversely affect the
internal controls as of the end of the second fiscal quarter.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
See "Note 10 to the Company's Unaudited Condensed
Consolidated Financial Statements" for the three
months ended June 30, 2004, which is incorporated
by reference.
Item 2. Changes in Securities, Use of Proceeds and Issuer
Purchases of Equity Securities
(e) Issuer Purchases of Equity Securities (Dollars and Shares in
millions except per share amounts)
Total Number
Of Shares Maximum
Average Repurchased Dollar Value
Total Price as Part of of Shares
Number Paid Publicly that May Yet Be
of Shares Per Announced Repurchased Under
Repurchased Share Program the Program
----------- --------- ----------- -----------------
January 1-January 31 0.3 $38.317 0.3 $239.5
February 1-February 29 0.4 38.872 0.7 223.2
March 1-March 31 1.0 38.562 1.7 183.4
April 1-April 30 0.9 39.623 2.6 149.2
May 1-May 31 1.0 39.787 3.6 109.7
June 1-June 30 1.0 41.444 4.6 67.9
------ ------ ------ ------
Total 4.6 39.675 4.6 67.9
====== ====== ====== ======
On December 17, 2003, the Company's Board of Directors
authorized and announced stock repurchase program under which the
Company may purchase up to an aggregate of $250.0 of its common
stock from time-to-time, beginning in the first quarter of 2004.
Item 4. Submission of Matters to a Vote of Security Holders
The following votes were provided by American Stock Transfer
& Trust Company in their proxy tabulation reports dated May 13,
2004:
Total outstanding shares of Laboratory Corporation
of America Holdings(NEW): 143,014,042
Total shares voted 128,995,046
Votes Authority
For Withheld
----------- -----------
Election of the members
of the Board of Directors:
Thomas P. Mac Mahon 127,736,466 1,258,580
Jean-Luc Belingard 128,274,491 720,555
Wendy E. Lane 126,998,863 1,996,183
Robert E. Mittelstaedt, Jr. 128,296,535 698,511
Andrew G. Wallace, MD 128,252,670 742,376
M. Keith Weikel 128,296,529 698,517
Craig M. Watson 128,295,455 699,591
Item 4. Submission of Matters to a Vote of
Security Holders- Continued
Votes Votes Votes Broker
For Against Abstained Non-Votes
----------- --------- --------- ---------
Approval of the Amendments
To the Laboratory Corporation
of America Holdings 1997
Employee Stock Purchase Plan 100,350,134 1,534,136 331,706 26,779,070
Ratification of the
appointment of
PricewaterhouseCoopers LLP
as the Company's independent
accountants for the fiscal
year ending December 31, 2004 127,496,560 1,215,663 282,823 --
Total outstanding shares of Laboratory Corporation
of America Holdings (OLD): 40,863
Total shares voted 4,722
Votes Votes
For Withheld
--------- ---------
Election of the members
of the Board of Directors:
Thomas P. Mac Mahon 4,622 100
Jean-Luc Belingard 4,722 0
Wendy E. Lane 4,722 0
Robert E. Mittelstaedt, Jr. 4,722 0
Andrew G. Wallace, MD 4,722 0
M. Keith Weikel 4,722 0
Craig M. Watson 4,722 0
Votes Votes Votes
For Against Abstained
------ -------- ---------
Approval of the Amendment to the
Laboratory Corporation of America
Holdings 1997 Employee Stock
Purchase Plan 3,285 0 1,437
Ratification of the appointment of
PricewaterhouseCoopers LLP as the
Company's independent accountants
for the fiscal year ending
December 31, 2004: 3,285 0 1,437
Item 4. Submission of Matters to a Vote of
Security Holders- Continued
In addition, certain shares of National Health Laboratories
Holdings Inc. (NHL) which have not been converted to Company shares
were eligible to vote at the annual meeting and were voted as follows:
Total outstanding NHL shares: 116
Total shares voted: 5
Votes Votes
For Withheld
-------- --------
Election of the members
of the Board of Directors:
Thomas P. Mac Mahon 5 0
Jean-Luc Belingard 5 0
Wendy E. Lane 5 0
Robert E. Mittelstaedt, Jr. 5 0
Andrew G. Wallace, MD 5 0
M. Keith Weikel 5 0
Craig M. Watson 5 0
Votes Votes Votes
For Against Abstained
------- ------- ---------
Approval of the Amendment to the
Laboratory Corporation of America
Holdings 1997 Employee
Stock Purchase Plan 5 0 0
Ratification of the appointment of
PricewaterhouseCoopers LLP as the
Company's independent accountants
for the fiscal year ending
December 31, 2004: 5 0 0
Item 5. Other Information
Senior Executive Transition Policy
In April 2004, the Compensation Committee recommended to the Board of
Directors, and the Board adopted, a Senior Executive Transition
Policy (the "Policy").
An Executive Officer is eligible for benefits under this Policy if:
(1) he or she held office as the President/CEO or an Executive Vice
President on or after April 1, 2004; (2) at the time of his or her
voluntary termination, has been an Executive Vice President or
President/CEO of LabCorp for at least five years; (3) has been
credited with at least 10 years of service under the LabCorp
Employees' Retirement Savings Plan at their termination date; and (4)
has entered into a non-competition agreement with the Company within
30 days of the adoption of the Policy or his or her appointment as an
Executive Vice President or President/CEO. If a qualifying executive
resigns before attaining age 65, the departed executive's restricted
stock and stock option awards will continue to vest and be
exercisable on the same terms as if the executive had continued his
or her employment with LabCorp. The benefits of the Policy will be
available only if the executive officer complies with the terms of
the Policy regarding (a) minimizing any possible adverse effect on
shareholders of his or her announcement of and statements regarding,
a decision or intention to terminate employment before age 65; (b)
the reasonableness of the period between his or her announcement of a
decision or intention to retire and the announced and/or actual
termination date; and (c) compliance with an individualized plan to
be developed by the Board of Directors for the transition of his or
her duties to others, including a successor.
Each of the Company's Executive Officers as of the adoption of
the policy entered into a non-competition agreement with the
Company within the time periods set forth above.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
10.1 Laboratory Corporation of America Holdings Senior Executive
Transition Policy
31.1 Certification pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002 by the Chief
Executive Officer
31.2 Certification pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 by the Chief
Financial Officer
32 Certification pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 by the Chief
Executive Officer and the Chief Financial
Officer
(b) Reports on Form 8-K
N/A
S I G N A T U R E S
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By:/s/THOMAS P. MAC MAHON
---------------------------
Thomas P. Mac Mahon
Chairman, President and
Chief Executive Officer
By:/S/WESLEY R. ELINGBURG
---------------------------
Wesley R. Elingburg
Executive Vice President,
Chief Financial Officer and
Treasurer
August 4, 2004
EXHIBIT 10.1
Laboratory Corporation of America Holdings
Senior Executive Transition Policy
This Senior Executive Transition Policy ("the Policy") is
adopted to state in a single document the policy of Laboratory
Corporation of America Holdings ("LabCorp") regarding Awards made
under Stock Incentive Plans to a Senior Executive if the Senior
Executive thereafter voluntarily terminates employment with LabCorp
before reaching age 65. For purposes of this Policy, the term
"Senior Executive" means a duly appointed President/CEO or Executive
Vice President of LabCorp. The term "Stock Incentive Plan" means the
Laboratory Corporation of America Holdings 1994 Stock Option Plan,
the Laboratory Corporation of America Holdings 2000 Stock Option
Plan, and any plan of a like kind that may be adopted hereafter. The
term "Award" means an Award as defined in a Stock Incentive Plan.
1. This Policy applies only to Eligible Senior Executives. An
"Eligible Senior Executive" is a Senior Executive who has
satisfied the requirements of Paragraph 2 of this Policy
(relating to a Confidentiality/Non-Compete Letter), who held
office as the President/CEO or an Executive Vice President of
LabCorp on or after April 1, 2004, and who at the time of his or
her voluntary termination has served as a Senior Executive of
LabCorp for at least five years and has been credited with at
least ten "Years of Service" as defined in the Laboratory
Corporation of America Employees' Retirement Savings Plan.
2. A Senior Executive satisfies the requirement of this Paragraph 2
of the Policy if he or she executes a Confidentiality/Non-
Compete Letter substantially in the form attached as Exhibit A
within 30 days of the later of the adoption of this Policy or
his or her appointment as a Senior Executive, and if he or she
executes such amended forms of such a letter as may reasonably
be required by the Board of Directors from time to time.
3. If an Eligible Senior Executive resigns from office and
terminates employment with LabCorp and its affiliates before
reaching age 65, and the Compensation Committee finds that the
Eligible Senior Executive's transition satisfies the transition
requirements described in Paragraph 4 of this Policy, then
LabCorp, acting through the Compensation Committee of the Board
of Directors, will take all steps necessary and proper to cause
all Unexpired Awards to continue to be eligible for vesting and
to continue to be or become exercisable, payable, or eligible
for the termination of restrictions (as the case may be)
following termination of employment on the same terms and
conditions as if the Eligible Senior Executive had remained
employed by LabCorp during the original exercise period (or, in
the case of an Eligible Senior Executive who dies following
resignation from office and termination of employment, as if the
Eligible Senior Executive had remained so employed through the
date of death). An "Unexpired Award" means an Award granted to
the Eligible Senior Executive that had not expired and, in the
case of an Award that is an option, had not been exercised; in
the case of an Award that consists of restricted stock, had not
yet become free of restrictions; or, in the case of any other
Award, had not become payable as of the date of his or her
termination of employment with LabCorp.
4. The transition requirements referred to in Paragraph 3 of this
Plan are as follows:
(a) the Eligible Senior Executive's announcement of a decision
or intention to terminate before age 65 ("Announcement"), and
his or her subsequent public statements regarding his or her
decision or intention to terminate employment, are each made at
a time and in a manner reasonably calculated to minimize any
adverse effect the Announcement and/or any such statement might
have on the shareholders of LabCorp;
(b) the Eligible Senior Executive's Announcement, his or her
announced termination date, and (if different) his or her actual
termination date, whether considered individually or in
conjunction with the dates of the Announcement, the scheduled
termination dates, and/or the actual termination dates of any
other Senior Executives, do not occur within a period of time
that the Compensation Committee finds unreasonably short;
(c) following his or her Announcement, the Eligible Senior
Executive cooperates to the full satisfaction of the
Compensation Committee in the Board of Directors' development of
a plan (the "Transition Plan") for the transition of his or her
duties to others, including his or her successor; and the
Eligible Senior Executive executes his or her duties under the
Transition Plan to the full satisfaction of the Compensation
Committee. A Senior Executive's duties under a Transition Plan
may include (without limitation) taking all steps assigned to
him or her by the Board in connection with the search for and/or
selection of a successor, and active cooperation in training a
successor and fully familiarizing the successor with sources of
relevant information necessary to carrying out the successor's
duties.
5. This Policy may be modified, terminated, or amended at any time
by the Compensation Committee, provided, however, that no
modification, termination, or amendment of the Policy adopted
after a Senior Executive has made an Announcement will apply to
such Senior Executive without his or her written consent.
EXHIBIT A
[NAME]
President OR Executive Vice President
Laboratory Corporation of America Holdings
430 S. Spring Street, First Floor
Burlington, NC 27215
Dear ________________:
This letter is intended to memorialize your agreement, as the
_________________________ of Laboratory Corporation of America
Holdings ("the Company"), to certain duties of confidentiality, non-
competition, and similar matters during your employment, and
following your termination of employment, with the Company and any of
its affiliates (collectively, "LabCorp"). If you sign and return
this letter on or before _________ __, 2004, you will satisfy the
requirement of Section 2 of the Senior Executive Transition Policy
for being an "Eligible Senior Executive" as defined in that Policy.
Defined Terms. For purposes of this letter, "Laboratory Testing"
refers to the collection for testing and/or testing of specimens from
human beings for the purposes of diagnosis, treatment, or care of
disease or illness; monitoring or providing data for the analysis of
a regimen of treatment, a therapy, or a diagnostic or therapeutic
procedure; and/or detection or analysis of the presence or absence of
factors, chemicals or compounds. "Clinical Trial" refers to
assembling, validating, or analyzing data relating to the safety or
effectiveness of a drug or medical device.
Receipt of Confidential Information. You acknowledge that in the
course of your employment with LabCorp, you have developed and will
develop an extensive knowledge of LabCorp's business, including but
not limited to business strategies, cost information, marketing
information, product and service information, new products and
services under development, and plans for the expansion of product
and service lines (including, without limitation, plans for the
acquisition or licensing of intellectual property relating to
Laboratory Testing). In addition, you acknowledge that in your
employment you have access to information regarding LabCorp's
business plans, sales methods, and customers on a corporate-wide
basis in every market in which LabCorp conducts business. The
knowledge and information referred to above will be referred to as
"Confidential Information."
Competition. You and the Company agree that LabCorp will suffer
significant and irreparable injury, for which damages at law would
not be a measurable or adequate remedy, if you become employed by any
corporation or entity that competes with LabCorp or if you provide
services to any such corporation or entity in any other capacity that
would permit you to take advantage of the Confidential Information
acquired by you during the course of your employment with LabCorp
(including by breaching any of the numbered covenants contained in
this paragraph). Accordingly, you agree that during your employment
by LabCorp and for a period of two (2) years following your
termination of employment, you will not, directly or indirectly:
1. Become employed by or otherwise become interested in (as
owner, stockholder, partner, co-venturer, director, officer,
employee, agent, consultant, or otherwise) any corporation or
entity that is engaged (a) in the business of Laboratory Testing
in the United States and/or Canada at a location that is within
five (5) miles of any location at which one or more employees of
LabCorp is regularly engaged in any aspect of the business of
Laboratory Testing (including, without limitation, any regular
collection site served by LabCorp); or (b) that is engaged in
the business of Clinical Trials in a country in which LabCorp is
engaged in the business of Clinical Trials. This paragraph
shall not prevent you from holding not more than five (5)
percent of the outstanding securities of any class of any
publicly traded company, other than a company primarily engaged
in Laboratory Testing.
2. Solicit sales or business from any corporation or entity that
was a customer of LabCorp within the one-year time period
preceding your termination of employment provided, however, that
the solicitation of sales of products or services not offered by
LabCorp at the time of such solicitation shall not be deemed a
violation of this provision.
3. Employ or retain, or arrange to have any other person or
entity employ or retain, any person who shall have been employed
or retained by LabCorp as a director or officer at any time
during the one-year time period preceding the termination of
your employment.
4. Attempt to influence any director or officer of LabCorp to
terminate or modify his or her employment arrangement with
LabCorp.
You agree that the foregoing restrictions are necessary for the
reasonable and proper protection of the Company; are reasonable in
respect to subject matter, length of time, geographic scope, customer
scope, and scope of activity to be restrained; and are not unduly
harsh and oppressive so as to deprive you of a livelihood or to
unduly restrict your opportunity to earn a living after termination
of your employment with the Company.
Confidentiality. During the term of your employment with LabCorp and
thereafter, except as required by or pursuant to law, you shall not,
without the written consent of the Board or a person authorized
thereby, disclose to any person, other than an employee of LabCorp or
a person to whom disclosure is reasonably necessary or appropriate in
connection with the performance by you of your duties as a Senior
Executive of LabCorp, any Confidential Information or Business
Information obtained by you while in the employ of LabCorp. The term
"Business Information" means any information pertaining to LabCorp's
conduct of its Laboratory Testing and/or Clinical Trial business that
is not readily and easily available to the public or to those in
LabCorp's industry, including, without limitation, LabCorp's prices,
pricing methods, costs, profits, profit margins, suppliers,
procedures, processes, research and development projects, data,
goals, activities, business strategies, marketing techniques, the
identities or addresses of LabCorp's employees, the functions of
LabCorp's employees, and any customer-related information.
Property. During the term of this Agreement, you shall not make,
copy, maintain, distribute, divulge the contents of, or remove from
LabCorp's offices or premises any documents, records, or similar
materials containing Confidential Information or Business Information
unless necessary or appropriate in accordance with your duties and
responsibilities as [President OR Executive Vice President]. Upon
termination of your employment with LabCorp, you shall leave with or
immediately return to LabCorp all originals and copies of the
foregoing LabCorp property then in your possession, whether prepared
by you or by others.
Duty of Loyalty/Nondisparagement. During the term of your employment
and for a period of five years following your termination of
employment, you will not (except as required by or pursuant to law)
communicate to anyone, whether by word or deed, whether directly or
through any intermediary, and whether expressly or by suggestion or
innuendo, any statement, whether characterized as one of fact or of
opinion, that is intended to cause or that reasonably would be
expected to cause any person to whom it is communicated to have (1) a
lowered opinion of the Company or any affiliate, including a lowered
opinion of any products manufactured, sold, or used by, or any
services offered or rendered by the Company or any affiliate; and/or
(2) a lowered opinion of the creditworthiness or business prospects
of the Company or any affiliate.
Interpretation and Enforcement. You and the Company agree that this
letter will be interpreted and construed under the laws of North
Carolina (exclusive of any laws relating to choice of law in the
event of conflicts of law and of any principle causing ambiguities to
be construed against the drafter), and that the covenants contained
in the Competition portion of this letter will be construed and
interpreted so as to permit their enforcement to the maximum extent
permitted thereunder (including, to the extent necessary, by treating
each provision of this letter as severable and separately
enforceable, and/or by reforming any such separate provisions to the
minimum extent necessary to permit enforcement of such covenants to
the fullest extent permitted). You consent to the exclusive
jurisdiction of the courts of North Carolina over any action or
proceeding relating to the validity and/or construction of this
letter, and agree that you will not bring or remove any such action
or proceeding other than in or to a court established by the State of
North Carolina.
If this Agreement is acceptable to you, please sign and date this
letter where indicated below.
Laboratory Corporation of America Holdings
By:__________________________________
Accepted:
______________________________ ___/___/04
[NAME OF SENIOR EXECUTIVE]
[TITLE]
EXHIBIT 31.1
Certification
I, Thomas P. Mac Mahon, certify that:
1. I have reviewed this quarterly report on Form 10-Q of
Laboratory Corporation of America Holdings;
2. Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant's other certifying officer and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during
the period in which this report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this
report based on such evaluation; and
c) disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially
affect, the registrant's internal control over financial
reporting; and
5. The registrant's other certifying officers and I have
disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant's auditors
and the audit committee of registrant's board of directors (or
persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial
information; and
b) any fraud, whether or not material, that involves management
or other employees who have a significant role in the
registrant's internal control over financial reporting.
Date: August 4, 2004
-----------------
/s/ THOMAS P. MAC MAHON
-----------------------
Thomas P. Mac Mahon
Chief Executive Officer
EXHIBIT 31.2
Certification
I, Wesley R. Elingburg, certify that:
1. I have reviewed this quarterly report on Form 10-Q of
Laboratory Corporation of America Holdings;
2. Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant's other certifying officer and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during
the period in which this report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this
report based on such evaluation; and
c) disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially
affect, the registrant's internal control over financial
reporting; and
5. The registrant's other certifying officers and I have
disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant's auditors
and the audit committee of registrant's board of directors (or
persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial
information; and
b) any fraud, whether or not material, that involves management
or other employees who have a significant role in the
registrant's internal control over financial reporting.
Date: August 4, 2004
-----------------
/s/ WESLEY R. ELINGBURG
-----------------------
Wesley R. Elingburg
Chief Financial Officer
EXHIBIT 32
Written Statement of
Chief Executive Officer and Chief Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18
U.S.C. Section 1350)
The undersigned, the Chief Executive Officer and the Chief
Financial Officer of Laboratory Corporation of America Holdings
(the "Company"), each hereby certifies that, to his knowledge on
the date hereof:
(a) the Form 10-Q of the Company for the Period Ended June
30, 2004 filed on the date hereof with the Securities and
Exchange Commission (the "Report") fully complies with the
requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and
(b) information contained in the Report fairly presents,
in all material respects, the financial condition and results of
operations of the Company.
By:/s/THOMAS P. MAC MAHON
--------------------------------
Thomas P. Mac Mahon
Chief Executive Officer
August 4, 2004
By:/s/WESLEY R. ELINGBURG
---------------------------------
Wesley R. Elingburg
Chief Financial Officer
August 4, 2004